SCHEDULE 13G/A: Vanguard Group Discloses 7.75% Stake in Travere Therapeutics Inc. Common Stock
Beneficial Ownership Report
The Vanguard Group has filed an amended Schedule 13G, reporting a 7.75% beneficial ownership stake in Travere Therapeutics Inc. as of December 31, 2024.
Summary
- The Vanguard Group filed Amendment No. 7 to Schedule 13G concerning its beneficial ownership of Common Stock in Travere Therapeutics Inc.
- As of December 31, 2024, The Vanguard Group beneficially owned an aggregate of 6,742,165 shares of Travere Therapeutics Inc. Common Stock.
- This ownership represents 7.75% of the total class of securities outstanding.
- Vanguard holds sole voting power over 0 shares and shared voting power over 53,801 shares.
- Vanguard holds sole dispositive power over 6,609,593 shares and shared dispositive power over 132,572 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Travere Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a routine beneficial ownership disclosure (Schedule 13G Amendment No. 7) by a passive institutional investor, The Vanguard Group. It provides factual information about ownership percentages and voting/dispositive powers, without containing any positive or negative operational or financial news about the issuer, Travere Therapeutics Inc. Therefore, the sentiment is neutral.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
This filing is a routine disclosure by a large asset manager, The Vanguard Group, indicating its passive investment stake in Travere Therapeutics Inc. It does not provide specific insights into broader industry trends or competitive positioning beyond the fact that a major institutional investor maintains a significant position in the company.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming Vanguard's continued passive investment in the company.
Key Dates
| Date | Description |
|---|---|
| 12/31/2024 | Date of event which requires filing of this statement (beneficial ownership calculation date). |
| 01/31/2025 | Date of filing and signature by The Vanguard Group. |
Keywords
Travere Therapeutics Inc., Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, TRVR
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.